• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Antares Pharma, Inc. - Common Stock (NQ: ATRS )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Antares Pharma, Inc. - Common Stock

    < Previous 1 2 Next >
    Looking Into Antares Pharma's Return On Invested Capital
    Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter. 
    Via Benzinga
    ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
    From Kahn Swick & Foti, LLC
    Via Business Wire
    ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS
    From Kuznicki Law PLLC
    Via Business Wire
    ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
    Via Benzinga
    Antares Pharma: Q4 Earnings Insights
    Antares Pharma (NASDAQ:ATRS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
    Upgrades 
    Via Benzinga
    Looking Into Antares Pharma Inc's Recent Short Interest
    Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently reported that it has 4.49 million shares sold short, which is... 
    Via Benzinga
    Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
    Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
    Via FinancialNewsMedia
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Gainers 
    Via Benzinga
    Why Is Sierra Oncology (SRRA) Stock Up Today?
    Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
    Via InvestorPlace
    Why Antares Pharma Stock Is Soaring Today
    Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing... 
    Via Benzinga
    Why Is BriaCell (BCTX) Stock Moving Today?
    BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. 
    Via InvestorPlace
    Why Is Antares Pharma (ATRS) Stock Up Today?
    Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). 
    Via InvestorPlace
    Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More
    Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
    Via Benzinga
    Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
    GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
    Via Investor's Business Daily
    Futures Rise As Earnings Season Begins
    On the geopolitical front, the presidents of Poland and the three Baltic states are heading to Kyiv in a show of support that follows the visits of other leaders to the Ukrainian capital, including... 
    Via Talk Markets
    The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
    Via Benzinga
    ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders
    From Halper Sadeh LLP
    Via Business Wire
    Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13
    Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters According to two people with close knowledge of the matter, BlackRock, Inc. (NYSE: BLK) plans to launch... 
    Via Benzinga
    Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
    Via InvestorPlace
    The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
    Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
    Via Benzinga
    Antares Pharma's Return On Capital Employed Overview
    According to Benzinga Pro, during Q4, Antares Pharma (NASDAQ:ATRS) earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48.... 
    Via Benzinga
    The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
    Via Benzinga
    Earnings Scheduled For March 3, 2022
    Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
    Via Benzinga
    Earnings Outlook For Antares Pharma
    Antares Pharma (NASDAQ:ATRS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
    Via Benzinga
    Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
    The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
    Via Benzinga
    FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
    The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program... 
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.